Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)

Articolo

Data di Pubblicazione:

2009

Citazione:

Valentini, V., Aristei, C., Glimelius, B., Minsky, B., Beets Tan, R., Borras, J., Haustermans, K., Maingon, P., Overgaard, J., Pahlman, L., Quirke, P., Schmoll, H., Sebag Montefiore, D., Taylor, I., Van Cutsem, E., Van De Velde, C., Cellini, N., Aranda, E., Latini, P., Blomqvist, L., Bosset, J., Brown, G., Bujko, K., Ectors, N., Gerard, J., Glynne Jones, R., Heald, R., Hohenberger, W., Holm, T., Laurberg, S., Leer, J., Marijnen, C., Nagtegaal, I., Rodel, C., Rutten, H., Scheithauer, W., Willet, C., Coco, C., Gambacorta, M. A., Genovesi, D., Lupattelli, M., Mantello, G., Valvo, E., Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2), <>, 2009; 92 (2): 148-163. [doi:10.1016/j.radonc.2009.06.027] [http://hdl.handle.net/10807/28543]

Abstract:

During the first decade of the 21st century a number of important European randomized studies were published. In order to help shape clinical practice based on best scientific evidence from the literature, the International Conference on 'Multidisciplinary Rectal Cancer Treatment: Looking for an European Consensus' (EURECA-CC2) was organized in Italy under the endorsement of European Society of Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO), and European Society of Therapeutic Radiation Oncology (ESTRO).

Tipologia CRIS:

Articolo in rivista, Nota a sentenza

Keywords:

Combined Modality Therapy; Cost-Benefit Analysis; Diet; Humans; Neoplasm Staging; Quality of Life; Rectal Neoplasms; Risk Factors

Elenco autori: